Deferring systemic therapy may improve survival outcomes in carefully selected patients with metastatic renal cell carcinoma, new data suggest.

A University of Kentucky Markey Cancer Center study shows that a targeted form of radiation therapy can be safely delivered ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

Serial metastasis-directed radiotherapy extended time off systemic therapy while maintaining favorable progression-free and overall survival in patients with oligometastatic clear-cell renal cell ...

Hepatocellular carcinoma (HCC) management is rapidly evolving as systemic therapies and locoregional treatments are increasingly combined across disease ...

The results of this study highlight the need for more research into how treatment at the end of life is shaped by oncologists’ unique treatment propensities, according to researchers. Oncologists’ ...

Select patients with oligometastatic ccRCC might be managed with a period of metastasis-directed therapy alone. Serial metastasis-directed radiation therapy may delay systemic therapy in clear cell ...

Hi, I'm Matt. As a licensed marriage and family therapist (LMFT), my expertise is in reconnecting spouses and family members who genuinely seek to change their relationship. However, I also excel at ...